Response to FMT safety alert issued by the FDA

EnteroBiotix is aware of a safety alert issued by the FDA on 13/06/2019 regarding two patients who acquired Extended Spectrum Beta-Lactamase (ESBL)-producing Escherichia coli infections after receiving faecal microbiota transplantation (FMT). In the alert, the FDA state that the faecal microbiota transferred into the patients was derived from a donor that carried the ESBL producing […]

Continue reading

EnteroBiotix secure key additional MHRA license and announces regulatory milestones

MHRA MIA (IMP) license enables international clinical trial manufacture and distribution  EnteroBiotix meets with European Medicines Agency Innovation Task Force (ITF) in Amsterdam Founding member of Intestinal Microbiome Medicine European Task Group (IMM-ETG) Aberdeen, Scotland and Cambridge, MA, 19 June 2019 – EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, today […]

Continue reading

EnteroBiotix secures £2m seed extension investment and opens new office in Boston, USA

ABERDEEN, Scotland & CAMBRIDGE, Mass. EnteroBiotix, a leading clinical stage microbiome therapeutics company headquartered in Aberdeen, Scotland, has closed an oversubscribed seed extension investment and is set for international expansion following the opening of a new office in Boston, US. EnteroBiotix secures £2m seed extension investment, strengthens leadership position in microbiome therapeutics and opens new […]

Continue reading

EnteroBiotix announces MHRA license approval and strengthened senior management team

ABERDEEN, Scotland–EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to further its therapeutic and product pipeline. EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of […]

Continue reading

EnteroBiotix unveils major NHS collaboration during visit by Nicola Sturgeon

Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, recently welcomed First Minister Nicola Sturgeon and Scotland’s Chief Medical Officer Catherine Calderwood to its pioneering manufacturing facility and laboratories in Aberdeen as the firm progresses towards commercialisation of its products. Founded in 2017 by […]

Continue reading

EnteroBiotix celebrates success in Herald Scotland innovation awards

Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that the Company’s CEO, James McIlroy, was awarded the title of ‘Young Pioneer of the Year’ at the inaugural Herald Scotland business awards. The event, held at Glasgow Science Centre, recognised and […]

Continue reading

EnteroBiotix Raises £500,000 In Oversubscribed Seed Investment

Aberdeen, Scotland –EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that it has raised £500,000 in an oversubscribed seed round of investment. The financing was led by Equity Gap and supported by the Scottish Investment Bank, the investment arm of Scottish Enterprise. […]

Continue reading